LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

Schrodinger Inc

Fechado

SetorSaúde

11.79 4.43

Visão Geral

Variação de preço das ações

24h

Atual

Mín

11.25

Máximo

11.98

Indicadores-chave

By Trading Economics

Rendimento

10M

-33M

Vendas

-435K

54M

Margem de lucro

-60.369

Funcionários

891

EBITDA

10M

-31M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+94.69% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-686M

827M

Abertura anterior

7.36

Fecho anterior

11.79

Sentimento de Notícias

By Acuity

63%

37%

312 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Schrodinger Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de fev. de 2026, 23:25 UTC

Ações em Alta

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 de fev. de 2026, 23:15 UTC

Ganhos

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 de fev. de 2026, 23:54 UTC

Conversa de Mercado

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 de fev. de 2026, 23:47 UTC

Ganhos

Ferrovial 4Q Net EUR197M >FER.MC

25 de fev. de 2026, 23:45 UTC

Ganhos

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 de fev. de 2026, 23:42 UTC

Ganhos

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 de fev. de 2026, 23:38 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Company's Business Operations Remain Normal >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 de fev. de 2026, 23:25 UTC

Ganhos

Trip.com FY EPS CNY47.67 >TCOM

25 de fev. de 2026, 23:06 UTC

Ganhos

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 de fev. de 2026, 23:01 UTC

Ganhos

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 de fev. de 2026, 23:00 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

25 de fev. de 2026, 23:00 UTC

Conversa de Mercado
Ganhos

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 de fev. de 2026, 22:56 UTC

Conversa de Mercado
Ganhos

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 de fev. de 2026, 22:43 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 de fev. de 2026, 22:40 UTC

Conversa de Mercado
Ganhos

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 de fev. de 2026, 22:40 UTC

Ganhos

Karoon Energy Says Search for New CFO Well Advanced

25 de fev. de 2026, 22:39 UTC

Ganhos

Karoon Energy Says CFO Ray Church to Leave Company

25 de fev. de 2026, 22:39 UTC

Ganhos

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 de fev. de 2026, 22:38 UTC

Ganhos

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Comparação entre Pares

Variação de preço

Schrodinger Inc Previsão

Preço-alvo

By TipRanks

94.69% parte superior

Previsão para 12 meses

Média 22 USD  94.69%

Máximo 25 USD

Mínimo 18 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Schrodinger Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

4

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

23.27 / 26.13Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bullish Evidence

Longo Prazo

Very Strong Bullish Evidence

Sentimento

By Acuity

312 / 351 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat